Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the …
Biotechnology
US, Cambridge [HQ]
NTLA/Financial Reporting
Income Statements
9 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.00 | 16.00 | 26.00 | 30.00 | 43.00 | 57.00 | 33.00 | 52.00 | 36.00 | |
|
EPS
|
-0.70 | -1.42 | -1.88 | -1.98 | -1.96 | -2.24 | -3.66 | -6.37 | -5.42 | |
| Diluted in mil. | -0.70 | -1.42 | -1.88 | -1.98 | -1.96 | -2.24 | -3.66 | -6.37 | -5.42 | |
|
Profit
|
6.00 | 16.00 | 26.00 | 30.00 | -65.00 | -92.00 | 26.00 | 44.00 | 27.00 | |
| Gross Margin | 100.00 | 100.00 | 100.00 | 100.00 | -151.52 | -159.35 | 79.15 | 85.47 | 75.26 | |
| Pre Tax | -13.00 | -31.00 | -67.00 | -85.00 | -99.00 | -134.00 | -267.00 | -474.00 | -481.00 | |
| Profit Margin | -221.86 | -191.97 | -258.62 | -280.42 | -230.92 | -231.46 | -810.49 | -909.78 | -1,326.51 | |
| ETR | 7.55 | 3.49 | 4.43 | -6.48 | 6.87 | 6.45 | 3.05 | -3.38 | 10.34 | |
| Net | -12.00 | -31.00 | -67.00 | -85.00 | -92.00 | -125.00 | -259.00 | -490.00 | -481.00 | |
| Profit Margin | -205.11 | -191.97 | -258.62 | -280.42 | -215.06 | -216.52 | -785.76 | -940.52 | -1,326.51 | |
| EBITDA | -13.00 | -32.00 | -69.00 | -90.00 | -100.00 | -136.00 | -267.00 | -444.00 | -506.00 | |
| EBITDA Margin | -216.43 | -195.15 | -266.32 | -298.58 | -233.81 | -235.51 | -810.37 | -853.17 | -1,395.49 | |
| Operating Income | -13.00 | -32.00 | -69.00 | -90.00 | -106.00 | -136.00 | -267.00 | -458.00 | -515.00 | |
| Operating Margin | -221.86 | -195.15 | -266.32 | -298.58 | -246.78 | -235.51 | -810.37 | -879.04 | -1,420.51 | |
| Interest Income | - - | - - | 2.00 | 5.00 | 6.00 | 2.00 | 1.00 | 8.00 | 49.00 | |
| Loss | -19.00 | -48.00 | -95.00 | -121.00 | -149.00 | -194.00 | -300.00 | -510.00 | -551.00 | |
| Cost of Revenue | - - | - - | - - | - - | -108.00 | -150.00 | -6.00 | -7.00 | -8.00 | |
|
Operating Expenses
|
-19.00 | -48.00 | -95.00 | -121.00 | -149.00 | -194.00 | -300.00 | -510.00 | -551.00 | |
| R&D | -11.00 | -31.00 | -67.00 | -89.00 | -108.00 | -150.00 | -229.00 | -419.00 | -435.00 | |
| G&A | -8.00 | -16.00 | -28.00 | -32.00 | -41.00 | -44.00 | -71.00 | -90.00 | -116.00 | |
| SG&A | -8.00 | -16.00 | -28.00 | -32.00 | -41.00 | -44.00 | -71.00 | -90.00 | -116.00 | |
| S&M | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Depreciation and Amortization | - - | -1.00 | -2.00 | -4.00 | -5.00 | -6.00 | -6.00 | -7.00 | -8.00 | |
| Interest Expenses | - - | - - | - - | - - | - - | - - | - - | -8.00 | - - | |
| Other Expenses | - - | - - | -2.00 | -5.00 | -6.00 | -2.00 | - - | -16.00 | -15.00 | |
|
WA Shares Outstanding
|
17.00 | 22.00 | 36.00 | 43.00 | 47.00 | 55.00 | 70.00 | 76.00 | 88.00 | |
| Diluted | 17.00 | 22.00 | 36.00 | 43.00 | 47.00 | 55.00 | 70.00 | 76.00 | 88.00 |